MV-4-11（人急性單核細(xì)胞白血病細(xì)胞）
CBP60522
詢 價
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | MV-4-11 |
| Background: | The MV4-11 cell line was established by Rovera and associates from the blast cells of a 10-year-old male with biphenotypic B-myelomonocytic leukemia. The growth factor, granulocyte/macrophage colony-stimulating factor (GM-CSF), was required to establish this cell line and growth factors are necessary for its continuous proliferation in chemically defined medium [PubMed: 3496132]. |
| Species: | Homo sapiens, human |
| Tissue: | peripheral blood |
| Disease: | biphenotypic B myelomonocytic leukemia |
| Gender: | male,10 years |
| Morphology: | lymphoblast |
| Growth Mode: | suspension |
| DNA Profile: | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 13 D16S539: 11,12 D5S818: 11,12 D7S820: 8,9 THO1: 8,9.3 TPOX: 8,11 vWA: 14,15 Our Cell Line Authentication Service |
| Culture Medium: |
IMDM+20%FBS MV-4-11完全培養(yǎng)基，# CBP60522M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | CD4; Homo sapiens. CD10; Homo sapiens. CD15, human; Homo sapiens . CD4 (40-96%); CD10 (4-11%); CD15 (96-99%) |
| Genes Expressed: | CD4; Homo sapiens, CD10; Homo sapiens, CD15, human; Homo sapiens, CD4 (40-96%); CD10 (4-11%); CD15 (96-99%) |
| Comments: | This line can be propagated in medium supplemented with 10% FBS without the addition of growth factors. IL-3 can independently support the long-term growth of this cell line, but IL-3 antagonized the proliferation of MV4-11 cells in the presence of GM-CSF when both factors were used at very low concentrations. Granulocyte colony stimulating factor (G-CSF) synergized with GM-CSF in inducing proliferation of MV4-11 cells; G-CSF alone causes a transient stimulation of the cell line. This line was formerly designated ATCC HTB-189.Over 96% of these cells are positive by indirect immunofluorescence for the myelomonocytic antigen CD15, 40-96% are positive for the monocytic antigen CD4, and 4-11% are positive for CD10 [PubMed: 3500218]. For more information, please contact us (4008-750-250). |
